Calpain regulates thymidylate synthase-5-fluoro-dUMP complex levels associated with response to 5-fluorouracil in gastric cancer cells

Cancer Science

Volumn 102, Issue 8, 2011, Pages 1509-1515

  Nabeya, Yoshihiro ^a,b   Suzuki, Takao ^b   Furuya, Aki ^b   Koide, Naoki ^c   Ohkoshi, Motohiro ^d   Takiguchi, Masaki ^b   Ochiai, Takenori ^b   Matsubara, Hisahiro ^b   Hiwasa, Takaki ^b  

^a CHIBA CANCER CENTER   (Japan)

^b CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d Showagakuin Junior College   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 FLUORO DUMP; BENZYLOXYCARBONYLLEUCYLLEUCINAL; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CALPAIN; DRUG METABOLITE; FLUOROURACIL; ONO 3403; PROTEINASE INHIBITOR; SMALL INTERFERING RNA; THYMIDYLATE SYNTHASE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CONTROLLED STUDY; DOWN REGULATION; DRUG EXPOSURE; DRUG RESPONSE; DRUG SENSITIVITY; ENZYME REGULATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; STOMACH ADENOCARCINOMA; STOMACH CANCER; WESTERN BLOTTING;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CALPAIN; CELL LINE, TUMOR; FLUORODEOXYURIDYLATE; FLUOROURACIL; HUMANS; MICE; NIH 3T3 CELLS; PROTEASE INHIBITORS; STOMACH NEOPLASMS; THYMIDYLATE SYNTHASE;

EID: 79960415686     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.01978.x     Document Type: Article

References (38)

1. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer 2001; 37 (Suppl 8): S4-66.
2. Roukos DH. Current status and future perspectives in gastric cancer management. Cancer Treat Rev 2000; 26: 243-55.
3. Sakuramoto S, Sasako M, Yamaguchi T et al. ACTS-GC Group. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007; 357: 1810-20.
4. Kubota T. The role of S-1 in the treatment of gastric cancer. Br J Cancer 2008; 98: 1301-4.
5. Van Cutsem E, Haller D, Ohtsu A. The role of chemotherapy in the current treatment of gastric cancer. Gastric Cancer 2002; 5 (Suppl 1): 17-22.
6. Nabeya Y, Loganzo F Jr, Maslak P et al. The mutational status of p53 protein in gastric and esophageal adenocarcinoma cell lines predicts sensitivity to chemotherapeutic agents. Int J Cancer 1995; 64: 37-46.
7. Fujiwara H, Terashima M, Irinoda T et al. Quantitative measurement of thymidylate synthase and dihydropyrimidine dehydrogenase mRNA level in gastric cancer by real-time RT-PCR. Jpn J Cancer Res 2002; 93: 1342-50.
8. Ishikawa Y, Kubota T, Otani Y et al. Thymidylate synthetase and dihydropyrimidine dehydrogenase levels in gastric cancer. Anticancer Res 1999; 19: 5635-40.
9. Johnston PG, Lenz HJ, Leichman CG et al. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 1995; 55: 1407-12.
10. Habara K, Ajiki T, Kamigaki T, Nakamura T, Kuroda Y. High expression of thymidylate synthase leads to resistance to 5-fluorouracil in biliary tract carcinoma in vitro. Jpn J Cancer Res 2001; 92: 1127-32.
11. Beck A, Etienne MC, Cheradame S et al. A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil. Eur J Cancer 1994; 30A: 1517-22.
12. Etienne MC, Cheradame S, Fischel JL et al. Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol 1995; 13: 1663-70.
13. Ichikawa W, Uetake H, Shirota Y et al. Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Br J Cancer 2003; 89: 1486-92.
14. Liu J, Schmitz JC, Lin X et al. Thymidylate synthase as a translational regulator of cellular gene expression. Biochim Biophys Acta 2002; 1587: 174-82.
15. Forsthoefel AM, Pena MMO, Xing YY, Rafique Z, Berger FG. Structural determinants for the intracellular degradation of human thymidylate synthase. Biochemistry 2004; 43: 1972-9.
16. Chu E, Koeller DM, Johnston PG, Zinn S, Allegra CJ. Regulation of thymidylate synthase in human colon cancer cells treated with 5-fluorouracil and interferon-γ. Mol Pharmacol 1993; 43: 527-33.
17. Kirihara Y, Yamamoto W, Toge T, Nishiyama M. Dihydropyrimidine dehydrogenase, multidrug resistance-associated protein, and thymidylate synthase gene expression levels can predict 5-fluorouracil resistance in human gastrointestinal cancer cells. Int J Oncol 1999; 14: 551-6.
18. Mattar R, Yokozaki H, Yasui W, Ito H, Tahara E. p53 gene mutations in gastric cancer cell lines. Oncol (Life Sci Adv) 1992; 11: 7-12.
19. Jia L-Q, Osada M, Ishioka C et al. Screening the p53 status of human cell lines using a yeast functional assay. Mol Carcinog 1997; 19: 243-53.
20. Sekiya T, Fushimi M, Hori H, Hirohashi S, Nishimura S, Sugimura T. Molecular cloning and the total nucleotide sequence of the human c-Ha-ras-1 gene activated in a melanoma from a Japanese patient. Proc Natl Acad Sci USA 1984; 81: 4771-5.
21. Okabe H, Tsujimoto H, Fukushima M. Preparation of the antibodies against recombinant human thymidylate synthase for the detection of its intratumoral levels and the application to sensitivity-study of 5-fluorouracil. Oncol Rep 1997; 4: 685-90.
22. Sakamoto K, Sugimoto Y, Miyadera K, Oka T, Fukushima T. Preparation of anti-OPRT antibody for immunochemical detection (in Japanese with English abstract). Gan To Kagaku Ryoho (Jpn J Cancer Chemother) 2005; 32: 653-8.
23. r-1 cells derived from ultraviolet-sensitive human RSa cells. Cell Death Differ 2000; 7: 531-7.
24. Liu TL, Shimada H, Ochiai T et al. Enhancement of chemosensitivity toward peplomycin by calpastatin-stabilized NF-κB p65 in esophageal carcinoma cells: possible involvement of Fas/Fas-L synergism. Apoptosis 2006; 11: 1025-37.
25. Omura S, Fujimoto T, Otoguro K et al. Lactacystin, a novel microbial metabolite, induces neuritogenesis of neuroblastoma cells. J Antibiot 1991; 44: 113-6.
26. Hiwasa T, Sawada T, Sakiyama S. Cysteine proteinase inhibitors and ras gene products share the same biological activities including transforming activity toward NIH3T3 mouse fibroblasts and the differentiation-inducing activity toward PC12 rat pheochromocytoma cells. Carcinogenesis 1990; 11: 75-80.
27. Tsubuki S, Saito Y, Tomioka M, Ito H, Kawashima S. Differential inhibition of calpain and proteasome activities by peptidyl aldehydes of di-leucine and tri-leucine. J Biochem 1996; 119: 572-6.
28. Hiwasa T. Induction of apoptosis by a calpain stimulator, ONO-3403. Apoptosis 1996; 1: 75-80.
29. Hiwasa T, Nakamura Y, Ozaki T et al. Down-regulation of protein kinase Cα and γ and TPA-induced neurite formation in DAN-transformed neuroblastoma cells. FEBS Lett 1998; 440: 25-8.
30. Hiwasa T, Shimada H, Ochiai T et al. Decrease in growth factor receptors after treatment with serine protease inhibitor ONO-3403. Int J Oncol 2002; 20: 797-802.
31. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55-63.
32. Hiwasa T, Shimada H, Sakaida T et al. Drug-sensitivity pattern analysis for study of functional relationship between gene products. FEBS Lett 2003; 552: 177-83.
33. 2+-activated neutral protease. Biochemistry 1988; 27: 8122-8.
34. 2+-activated neutral protease (μ-CANP) deduced from its cDNA sequence. FEBS Lett 1986; 205: 313-7.
35. Hitomi K, Yokoyama A, Maki M. Expression of biologically active human calpastatin in baculovirus-infected insect cells and in Escherichia coli. Biosci Biotechnol Biochem 1998; 62: 136-41.
36. Ozaki T, Sakiyama S. Molecular cloning and characterization of a cDNA showing negative regulation in v-src-transformed 3Y1 rat fibroblasts. Proc Natl Acad Sci USA 1993; 90: 2593-7.
37. Sorimachi H, Ishiura S, Suzuki K. Structure and physiological function of calpains. Biochem J 1997; 328: 721-32.
38. Miyamoto S, Ochiai A, Boku N et al. Discrepancies between the gene expression, protein expression, and enzymatic activity of thymidylate synthase and dihydropyrimidine dehydrogenase in human gastrointestinal cancers and adjacent normal mucosa. Int J Oncol 2001; 18: 705-13.